Woodie Wilson, MD
Urology · Hattiesburg, MSNPI 1346354081
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.4%), education and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Intuitive Surgical at 36.4% of the total. Reporting peaked in 2022 at $2,874 and has fallen 75.2% since, to $714 in 2025.
Across 154 payments — averaging $37.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- Astellas Pharma US Inc$492
- Johnson & Johnson$462
- Tolmar Pharmaceuticals, Inc.$364
- Teleflex LLC$327
- Sumitomo Pharma America, Inc.$255
- plus $2K from 25 others
What the payments were for
- Travel & lodging$60310%
- Food & beverage$3,05052%
- Education$2,16537%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $2,120 |
| Astellas Pharma US Inc | 27 | $492 |
| Johnson & Johnson | 22 | $462 |
| Tolmar Pharmaceuticals, Inc. | 8 | $364 |
| Teleflex LLC | 4 | $327 |
| Sumitomo Pharma America, Inc. | 11 | $255 |
| Neotract Inc. | 4 | $225 |
| Pfizer | 12 | $190 |
| Medtronic | 2 | $189 |
| Coloplast | 6 | $164 |
| AbbVie(2 entities) | 12 | $163 |
| Cook Medical LLC | 5 | $129 |
| Boston Scientific | 2 | $109 |
| Siemens Medical Solutions USA, Inc. | 4 | $79 |
| Dendreon Pharmaceuticals LLC | 4 | $76 |
| Axonics, Inc. | 2 | $57 |
| Blue Earth Diagnostics | 3 | $57 |
| Accord Healthcare, Inc. | 1 | $50 |
| Bayer | 3 | $47 |
| Olympus America Inc. | 2 | $35 |
| Urogen Pharma, Inc. | 2 | $31 |
| Ferring Pharmaceuticals Inc. | 2 | $31 |
| Progenics Pharmaceuticals, Inc. | 1 | $27 |
| Merck | 1 | $25 |
| Rochester Medical Corporation | 2 | $24 |
| Urovant Sciences Inc | 1 | $16 |
| Kerecis Limited | 1 | $16 |
| Mission Pharmacal Company | 1 | $15 |
| Civco Medical Instruments | 1 | $15 |
| Laborie Medical Technologies Corp. | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$1,500
- Da Vinci Surgical System$584
- ELIGARD$287
- UroLift$231
- INTERSTIM$176
How this compares
$5,818 in reported general payments places this provider in the 70th percentile of 94 urology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 64 | $828,182 |
| ErleadaApalutamide | 21 | $248,220 |
| Thiola EcTiopronin | 11 | $145,779 |
| GemtesaVibegron | 192 | $128,232 |
| MyrbetriqMirabegron | 58 | $33,301 |
| Methenamine Hippurate | 120 | $9,380 |
| Tamsulosin Hcl | 813 | $9,356 |
| Finasteride | 551 | $7,480 |
| NitrofurantoinNitrofurantoin Macrocrystal | 125 | $5,254 |
| Trimethoprim | 33 | $3,393 |
| Ciprofloxacin Hcl | 613 | $3,161 |
| Bethanechol Chloride | 39 | $1,948 |
| Doxycycline Hyclate | 84 | $1,641 |
| Ketorolac Tromethamine | 91 | $1,557 |
| Tadalafil | 73 | $1,452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $492 | $861,483122 claims |
| Johnson & JohnsonErleada | $462 | $248,22021 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $255 | $128,232192 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 94 urology providers in Mississippi.
Other urology in Hattiesburg
- Sean DouglasHattiesburg$40K
- Kaitlen SchexnayderHattiesburg$10K
- Bradley SecrestHattiesburg$9K
- Deborah AzarHattiesburg$9K
- Hal LiddellHattiesburg$7K
- John MooreHattiesburg$6K
- Charles MooreHattiesburg$6K
- Randolph RossHattiesburg$2K
- Robert HollabaughSouthaven$17K
- Kristopher WhiteheadTupelo$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.